Aura Biosciences Inc at Jefferies Healthcare Conference Transcript
Good morning, and welcome to the Jefferies Global Healthcare Conference. My name is Suhani Doshi with the Jefferies investment banking team. And it is with great pleasure to introduce Elisabet de los Pinos, the CEO of Aura Biosciences. Thank you.
Good morning, everyone. It's a pleasure to be here this morning.
So let me introduce you to Aura Biosciences. We're a clinical-stage oncology company, and there are two things that clearly differentiate us. Number one is the type of drugs that we're developing. We have a platform that's using virus-like drug conjugates to treat many types of solid tumors.
The other thing that differentiates us is our initial approach in the clinic is for a field that has been deployed of any targeted therapy, which is ocular oncology or the early treatment of cancers in the eye. And we have a Phase 2 study that's going to readout this year and a Phase 3 that's coming up very soon. We are also applying our technology in urologic
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
